Leerink Partnrs Has Strong Estimate for MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities researchers at Leerink Partnrs boosted their FY2026 earnings per share estimates for Mirum Pharmaceuticals in a research note issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of $0.57 per share for the year, up from their prior forecast of $0.50. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ FY2027 earnings at $2.22 EPS.

Other equities research analysts have also issued reports about the company. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. Cowen began coverage on Mirum Pharmaceuticals in a research report on Wednesday, September 24th. They set a “buy” rating on the stock. JPMorgan Chase & Co. upped their price target on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. JMP Securities set a $81.00 price target on Mirum Pharmaceuticals and gave the company a “market outperform” rating in a research report on Thursday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Buy” and an average price target of $79.70.

Mirum Pharmaceuticals Stock Down 2.3%

Shares of Mirum Pharmaceuticals stock opened at $74.42 on Thursday. The stock’s fifty day moving average is $72.31 and its 200-day moving average is $55.49. The firm has a market capitalization of $3.74 billion, a PE ratio of -61.50 and a beta of 0.81. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $78.54.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.19. The company had revenue of $127.79 million for the quarter, compared to analyst estimates of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.Mirum Pharmaceuticals’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.52) earnings per share.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. CWM LLC boosted its stake in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after acquiring an additional 428 shares in the last quarter. Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Quarry LP acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at approximately $56,000. Osaic Holdings Inc. grew its holdings in Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after buying an additional 351 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Mirum Pharmaceuticals in the 1st quarter valued at approximately $89,000.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the sale, the senior vice president owned 2,426 shares in the company, valued at approximately $140,708. This represents a 80.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 9,578 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the sale, the chief financial officer owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. This trade represents a 19.34% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,578 shares of company stock worth $7,262,824. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.